Optima Capital’s Neumora Therapeutics NMRA Stock Holding History

Optima Capital’s Portfolio NMRA Stock Details NMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-270	Closed	-$483	–	895
2025 Q4	$483	Buy	+270	New	+$591	﹤0.01%	1269

Other funds holding NMRA

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

Optima Capital's NMRA Position: Q1 2026 in Review

Optima Capital sold out of Neumora Therapeutics (NMRA) in Q1 2026, closing a stake of 270 shares — an estimated $483 sold.

Optima Capital first reported a position in NMRA in Q4 2025 and held it in 1 quarter. The position peaked at $483 in Q4 2025. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

Optima Capital reported no remaining Neumora Therapeutics position as of Q1 2026 after selling out during the quarter.
Optima Capital sold 270 Neumora Therapeutics shares in Q1 2026, an estimated $483.
Optima Capital first reported a position in Neumora Therapeutics in Q4 2025 and held it in 1 quarter.
Optima Capital's Neumora Therapeutics position peaked at $483 in Q4 2025.
114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Optima Capital's 13F filing for Q1 2026, filed 5 May 2026.